Month: March 2020

REDWOOD CITY, Calif., March 18, 2020 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit frontier cancer targets, today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 10,590,090 providing, in part, composition of matter protection for its SHP2 inhibitors, including RMC-4630.  RMC-4630, the company’s investigational SHP2 inhibitor, is a potent and orally bioavailable small molecule that is designed to selectively inhibit the activity of SHP2, an upstream cellular protein that plays a central role in modulating cell survival and growth by transmitting signals from receptor tyrosine kinases to RAS.   “We have systematically built our SHP2 program intellectual property portfolio while advancing RMC-4630...

NEW YORK and TORONTO, March 18, 2020 (GLOBE NEWSWIRE) — NexTech AR Solutions (NexTech) (OTCQB: NEXCF) (CSE: NTAR) (FSE: N29), the leader in augmented reality for e-commerce and AR learning applications, has been experiencing an uptick in sales in its fast growing e-commerce division and its AR technology business segments. The company has multiple business segments that are benefiting from the new work from home (WFH) and shop from home (SFH) paradigm shifts that employers, business and governments have instituted due to the Coronavirus.Evan Gappelberg CEO of NexTech comments, “As consumers shop from home and stock up on food and household items to cope with the coronavirus outbreak, demand for supplies including HEPA vacuum cleaning bags and pet supplements is rapidly increasing, setting us up for a record breaking month in sales...

WASHINGTON, March 18, 2020 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Neal Ganguli as a Senior Managing Director and Automotive & Industrial Business Transformation Leader, enhancing the firm’s ability to provide performance improvement and transaction services to automotive and industrial manufacturers, as well as private equity clients investing in these sectors. He will work alongside Senior Managing Director and Automotive & Industrial Restructuring Leader David Woodward.Based in Detroit, Mr. Ganguli brings more than 20 years of experience executing large strategic and operational profitability and performance improvement programs for global industrial and automotive clients as well as private equity funds. He has led efforts across the business value chain, including product/market...

KELOWNA, British Columbia and EDMONTON, Alberta, March 18, 2020 (GLOBE NEWSWIRE) — Allied Corp. (“Allied” or the “Company”) (OTCQB: ALID), an international medical cannabis company focused on creating and providing targeted cannabinoid health solutions to address today’s medical issues, and Radient Technologies Inc. (“Radient”) (TSX Venture: RTI; OTCQX: RDDTF), a global commercial manufacturer of high quality cannabinoid-based ingredients, formulations and products, are pleased to announce they have signed a definitive agreement (the “Agreement”) as part of a three way agreement with the Dhaliwal Group (“Dhaliwal”) to manage the supply chain, manufacturing and sale of high quality CBD distillate and isolate.Under the terms of the Agreement, Allied will facilitate the supply and purchase of high quality CBD...

ANN ARBOR, Mich., March 18, 2020 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced the appointment of Alan Fuhrman as a Class III director, with a term expiring at the 2022 meeting of stockholders.“On behalf of the Lipid Management team and our directors, I am very pleased to welcome Alan to the Esperion board. His extensive financial leadership experience will be extremely valuable as Esperion transitions to both developing and commercializing oral, LDL-C lowering medicines,” said Tim Mayleben, president and chief executive officer of Esperion. “With the recent U.S. approvals of the NEXLETOLTM (bempedoic acid) and NEXLIZETTM (bempedoic acid and ezetimibe) tablets, we are poised to deliver on the commercial promise of our medicines while continuing to advance the development of oral, once-daily LDL-C lowering...

VANCOUVER, British Columbia, March 18, 2020 (GLOBE NEWSWIRE) — CloudMD Software & Services Inc. (CSE: DOC, OTCQB: DOCRF, Frankfurt: 6PH) (the “Company” or “CloudMD”), a Company focused on revolutionizing the delivery of healthcare, announces it anticipates closing the first tranche of its previously announced private placement financing of up to $3.0 million on Friday, March 20th.We are pleased to announce the anticipated closing of $2.3 million out of the $3.0 million fully committed and subscribed offering for CloudMD. We expect to close on the second and final tranche shortly after. While many of our syndicate and selling group partners have made important decisions regarding their business operations around COVID-19, it has presented some difficulties in coordinating administrative elements for paperwork. As previously announced...

Quarterly Total Revenues reached RMB2,848.3 million (US$409.1 million)iQuarterly Deliveries of the ES8 and the ES6 were 8,224 vehicles Full Year Total Revenues reached RMB7,824.9 million (US$1,124.0 million)Full Year Deliveries of the ES8 and the ES6 were 20,565 vehiclesSHANGHAI, China, March 18, 2020 (GLOBE NEWSWIRE) — NIO Inc. (“NIO” or the “Company”) (NYSE: NIO), a pioneer in China’s premium electric vehicle market, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2019.Operating Highlights for the Fourth Quarter and Full Year 2019Deliveries of vehicles were 8,224 in the fourth quarter of 2019 including 6,824 ES6s and 1,400 ES8s, compared with 4,799 vehicles delivered in the third quarter of 2019.Deliveries of vehicles were 20,565 in 2019, compared with 11,348 vehicles delivered...

At Skeljungur hf.´s AGM, which was held on March 5, 2020, shareholders authorized the Board of Directors of the Company to purchase shares in the Company, on the condition that the Company together with its subsidiaries shall only hold a maximum of 10% of the Company´s shares.The Board of Directors of Skeljungur hf. have decided to initiate a share buy-back program in accordance with the existing authorization. It is planned to buy up to 24,820,946 of the Company´s own shares, which corresponds to 1.25% of the issued share capital, although the amount of the repurchases shall not exceed ISK 250.000.000. The main purpose of the program is to reduce the issued share capital of the company.Purchases under the program shall be divided into numerous transactions, however the daily trade will not exceed 25% of the average daily volume of the...

Á aðalfundi Skeljungs hf., sem haldinn var 5. mars 2020, var stjórn félagsins veitt heimild til að kaupa hlutabréf í félaginu, fram að næsta aðalfundi, þó þannig að Skeljungur hf. ásamt dótturfélögum þess mega einungis eiga mest 10% hlutafjár félagsins.Stjórn Skeljungs hf. hefur tekið ákvörðun um framkvæmd endurkaupaáætlunar á grundvelli gildandi heimildar. Áætlað er að kaupa allt að 24.820.946 eigin hluti í félaginu eða sem samsvarar 1,25% af útgefnu hlutafé, þó þannig að fjárhæð endurkaupanna verði aldrei meiri en 250.000.000 kr. Markmið áætlunarinnar er að lækka útgefið hlutafé félagsins.Kaupin verða framkvæmd í áföngum, þó þannig að kaup hvers dags verða að hámarki 3.585.505 hlutir sem jafngildir 25% af meðaltali daglegra viðskipta með hlutabréf félagsins í Kauphöll Íslands í febrúar 2020. Endurgjald fyrir hvern hlut skal að hámarki...